Skip to main content
Premium Trial:

Request an Annual Quote

Syngenta, Chromatin Extend Gene Stacking Technology Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chromatin today announced an extension of its agreement with Syngenta Biotechology for use of Chromatin's gene stacking technology for soybean applications.

The deal builds on earlier agreements between the two firms. The original deal, forged in 2007, gave Syngenta non-exclusive rights to use Chromatin's technology for trait genes in corn and soybean. Two years later, Syngenta acquired exclusive worldwide research and commercial license rights to the technology for use in sugar cane.

The two firms today said that they have begun work to further the gene stacking technology for use on soybeans. They did not elaborate.

Terms of the extension were not disclosed.

Chromatin is based in Chicago and develops technologies for use in the agricultural, energy, chemical, nutritional, and pharmaceutical areas. Its gene stacking technology uses a plant's own DNA to deliver genes on a mini-chromosome, genetic elements built to deliver multiple traits "and accelerate the development of new products, providing new benefits to growers, industrial bioprocessors, and consumers," Chromatin said in a statement.

Syngenta is an agribusiness based in Basel, Switzerland, engaged in the development, manufacture, and marketing of products for the enhancement of crop yields and food quality.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.